Clinical trial · Observational
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
An Observational Study of the Treatment of Multiple Myeloma in Routine Clinical Practice
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of this observational study is to document and describe current treatment regimens and disease progression of patients with Multiple Myeloma (MMY). The aim of this registry is to provide accurate, descriptive information on the way Multiple Myeloma is treated in routine clinical practice. The registry will collect information related to the treatment received for Multiple Myeloma. About 3000 patients will take part in the study in about 28 countries. The registry will only collect information that is already in medical files regarding treatment. Patients will not be required to actively do anything in addition to what would be done without participating in this registry, nor will there be any procedures or interventions that are not already part of the current treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Any MMY treatment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 001
- description
- Any MMY treatment Any line of treatment for MMY
- interventionNames
- Other: Any MMY treatment
Primary outcomes (1)
- measure
- Description of current treatment regimens for MMY.
- timeFrame
- Every 3 months from baseline to 3 years after last patient recruited
Secondary outcomes (4)
- measure
- Utilisation of current treatment regimens for MMY
- timeFrame
- Every 3 months from baseline to 3 years after last patient recruited
- measure
- Quality of life and health economic parameters associated with MMY treatment regimens
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: \- Requires commencement of a new line of treatment for MMY at any stage, regardless of type of therapy selected. Exclusion Criteria: * Patients currently participating in another investigational study or clinical trial.
References
Publications (0)
Data not yet available